Affordable Access

Pharmacogenomics Related to Growth Disorders.

Hormone Research in Paediatrics
S. Karger AG
Publication Date
  • Biology
  • Medicine
  • Pharmacology


Growth disorders resulting in short stature are caused by a wide range of underlying pathophysiological processes. To improve height many of these conditions are treated with recombinant human growth hormone (rhGH). However, substantial inter-individual variability in growth response both in the short and long-term is recognised. Over the last decade, disease-specific growth prediction models have been developed that the clinician can use to define a child's potential response to rhGH and to optimise starting and maintenance doses of rhGH. These models, however, are not able to predict all the variations in treatment response. There has, therefore, been recent interest in using genetic information to contribute to the evaluation of responses to rhGH, including high-throughput technologies for assessing DNA markers (genome) and mRNA transcripts (transcriptome) as pharmacogenomic tools. This review will focus on how these pharmacogenomic approaches are being applied to growth disorders. © 2013 S. Karger AG, Basel.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Pharmacogenomics related to growth disorders.

on Hormone research in pædiatrics 2013

Genomics and pharmacogenomics of brain disorders.

on Current Pharmaceutical Biotech... April 2012

Pharmacogenomics of psychiatric disorders.

on Trends in pharmacological scie... February 2001

Pharmacogenomics and coagulation disorders.

on Methods in molecular medicine 2004
More articles like this..